IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients

Taihei Yamada, Michiko Aoyama-Ishikawa, Hayato Yamashita, Mayu Fujiwara, Makoto Usami, Takahiro Ueda, Mariko Terashima, Keisuke Kohama, Atsunori Nakao, Joji Kotani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Single nucleotide polymorphisms in the promoter of interleukin (IL)-18 (-607C/A and -137G/C) may affect the clinical course of inflammatory diseases. This study examined the relationship between the plasma IL18 levels, IL18 promoter polymorphism, and outcomes in the intensive care unit (ICU) setting. Patients and Methods: Plasma IL18 levels, IL18 promoter genotype, clinical variables, including APACHE II score, and mortality were examined in 70 ICU patients. Results: Plasma IL18 levels were significantly higher in patients who did not survive the ICU stay than in patients who survived, and were correlated with APACHE II score. When examined by IL18 promoter genotype, only patients with the -607CA genotype exhibited differences in IL18 expression between survivors and nonsurvivors. Conclusion: Plasma IL18 levels may predict outcome in patients with sepsis. IL18 promoter polymorphism, especially at -607, may increase IL18 production in some patients and might be useful in predicting the outcome of patients with sepsis in the ICU.

Original languageEnglish
Pages (from-to)391-396
Number of pages6
JournalIn Vivo
Volume28
Issue number3
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Intensive care units
Interleukin-18
Polymorphism
Intensive Care Units
Mortality
Plasmas
APACHE
Genotype
Sepsis
Single Nucleotide Polymorphism
Survivors
Nucleotides

Keywords

  • Interleukin-18
  • Promoter regions
  • Sepsis
  • Single nucleotide polymorphism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology
  • Medicine(all)

Cite this

Yamada, T., Aoyama-Ishikawa, M., Yamashita, H., Fujiwara, M., Usami, M., Ueda, T., ... Kotani, J. (2014). IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients. In Vivo, 28(3), 391-396.

IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients. / Yamada, Taihei; Aoyama-Ishikawa, Michiko; Yamashita, Hayato; Fujiwara, Mayu; Usami, Makoto; Ueda, Takahiro; Terashima, Mariko; Kohama, Keisuke; Nakao, Atsunori; Kotani, Joji.

In: In Vivo, Vol. 28, No. 3, 2014, p. 391-396.

Research output: Contribution to journalArticle

Yamada, T, Aoyama-Ishikawa, M, Yamashita, H, Fujiwara, M, Usami, M, Ueda, T, Terashima, M, Kohama, K, Nakao, A & Kotani, J 2014, 'IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients', In Vivo, vol. 28, no. 3, pp. 391-396.
Yamada T, Aoyama-Ishikawa M, Yamashita H, Fujiwara M, Usami M, Ueda T et al. IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients. In Vivo. 2014;28(3):391-396.
Yamada, Taihei ; Aoyama-Ishikawa, Michiko ; Yamashita, Hayato ; Fujiwara, Mayu ; Usami, Makoto ; Ueda, Takahiro ; Terashima, Mariko ; Kohama, Keisuke ; Nakao, Atsunori ; Kotani, Joji. / IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients. In: In Vivo. 2014 ; Vol. 28, No. 3. pp. 391-396.
@article{fc8ef60156d8460c85b0e323edd36c54,
title = "IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients",
abstract = "Background: Single nucleotide polymorphisms in the promoter of interleukin (IL)-18 (-607C/A and -137G/C) may affect the clinical course of inflammatory diseases. This study examined the relationship between the plasma IL18 levels, IL18 promoter polymorphism, and outcomes in the intensive care unit (ICU) setting. Patients and Methods: Plasma IL18 levels, IL18 promoter genotype, clinical variables, including APACHE II score, and mortality were examined in 70 ICU patients. Results: Plasma IL18 levels were significantly higher in patients who did not survive the ICU stay than in patients who survived, and were correlated with APACHE II score. When examined by IL18 promoter genotype, only patients with the -607CA genotype exhibited differences in IL18 expression between survivors and nonsurvivors. Conclusion: Plasma IL18 levels may predict outcome in patients with sepsis. IL18 promoter polymorphism, especially at -607, may increase IL18 production in some patients and might be useful in predicting the outcome of patients with sepsis in the ICU.",
keywords = "Interleukin-18, Promoter regions, Sepsis, Single nucleotide polymorphism",
author = "Taihei Yamada and Michiko Aoyama-Ishikawa and Hayato Yamashita and Mayu Fujiwara and Makoto Usami and Takahiro Ueda and Mariko Terashima and Keisuke Kohama and Atsunori Nakao and Joji Kotani",
year = "2014",
language = "English",
volume = "28",
pages = "391--396",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - IL18 production and IL18 promoter polymorphisms correlate with mortality in ICU patients

AU - Yamada, Taihei

AU - Aoyama-Ishikawa, Michiko

AU - Yamashita, Hayato

AU - Fujiwara, Mayu

AU - Usami, Makoto

AU - Ueda, Takahiro

AU - Terashima, Mariko

AU - Kohama, Keisuke

AU - Nakao, Atsunori

AU - Kotani, Joji

PY - 2014

Y1 - 2014

N2 - Background: Single nucleotide polymorphisms in the promoter of interleukin (IL)-18 (-607C/A and -137G/C) may affect the clinical course of inflammatory diseases. This study examined the relationship between the plasma IL18 levels, IL18 promoter polymorphism, and outcomes in the intensive care unit (ICU) setting. Patients and Methods: Plasma IL18 levels, IL18 promoter genotype, clinical variables, including APACHE II score, and mortality were examined in 70 ICU patients. Results: Plasma IL18 levels were significantly higher in patients who did not survive the ICU stay than in patients who survived, and were correlated with APACHE II score. When examined by IL18 promoter genotype, only patients with the -607CA genotype exhibited differences in IL18 expression between survivors and nonsurvivors. Conclusion: Plasma IL18 levels may predict outcome in patients with sepsis. IL18 promoter polymorphism, especially at -607, may increase IL18 production in some patients and might be useful in predicting the outcome of patients with sepsis in the ICU.

AB - Background: Single nucleotide polymorphisms in the promoter of interleukin (IL)-18 (-607C/A and -137G/C) may affect the clinical course of inflammatory diseases. This study examined the relationship between the plasma IL18 levels, IL18 promoter polymorphism, and outcomes in the intensive care unit (ICU) setting. Patients and Methods: Plasma IL18 levels, IL18 promoter genotype, clinical variables, including APACHE II score, and mortality were examined in 70 ICU patients. Results: Plasma IL18 levels were significantly higher in patients who did not survive the ICU stay than in patients who survived, and were correlated with APACHE II score. When examined by IL18 promoter genotype, only patients with the -607CA genotype exhibited differences in IL18 expression between survivors and nonsurvivors. Conclusion: Plasma IL18 levels may predict outcome in patients with sepsis. IL18 promoter polymorphism, especially at -607, may increase IL18 production in some patients and might be useful in predicting the outcome of patients with sepsis in the ICU.

KW - Interleukin-18

KW - Promoter regions

KW - Sepsis

KW - Single nucleotide polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84918576131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918576131&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 391

EP - 396

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 3

ER -